NCT05623592View on ClinicalTrials.gov

Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Giant Cell Arteritis
Interventions
DRUG

Methotrexate

17,5/15/10 mg Methotrexate subcutaneously

DRUG

Sodium chloride

Sodium chloride subcutaneously

Trial Locations (1)

Unknown

Medical Clinic and Polyclinic III Internal medicine Oncology, Hematology University Hospital Bonn, Rheumatology and Clinical Immunology, Bonn

All Listed Sponsors
lead

University of Bonn

OTHER